Lavanya Yohanathan

Hepatopancreatobiliary surgeon @ MHP, interest in transplant oncology. Mayo Clinic Alum. Opinions my own

[IHPBA @IHPBA]

On #IWD2026, IHPBA celebrates the achievements and leadership of #WomenInHPBSurgery. Today we proudly highlight Lavanya Yohanathan.

🌍✨ Celebrating International Women’s Day 2026 🌍✨

@LYohanathan @AHPBA #IWD2026 #GiveToGain

[Annals of Surgical Oncology @AnnSurgOncol]

Featured: Transplant Oncology—A New Frontier in #LiverCancer Care @LYohanathan

https://t.co/tm5fSi2Vux

@NabeelZafarMD
@SyedAAhmad5
@SocSurgOnc

[Lavanya Yohanathan @LYohanathan]

Neoadjuvant intent treatment for high risk hcc should be considered in patients. The data is there… let’s encourage this strategy!

[Beau Bosko Toskich, MD FSIR @BeauToskichMD]

⬇️DOWNSTAGING patients with #HCC and Macrovascular Invasion to curative intent should be a FIRST-LINE strategy.

It involves both local and systemic therapy. No room for turf nonsense. 🤝

📣"VP1-3 and normalize AFP"

Fight for your patients' BIG WIN. ⚔️ 🧩

#Y90 #immunotherapy
#SBRT #Transplant #Livertwitter @OncBrothers
@brunolarvol @ASTSChimera
@AASLDtweets @UHNTransplant

https://t.co/zaF29m6eqV

[Lavanya Yohanathan @LYohanathan]

@IswantoSucandy @AdventHealth @SSATNews @SAGES_Updates @IHPBA @AHPBA @socroboticsurg @NatRevGastroHep @TB_Times @TGHCares @USouthFlorida What were the main takeaways! I remember these discussions to be extremely helpful and useful! A summary slide for the rest of us would be wonderful on x !

[Lavanya Yohanathan @LYohanathan]

Join me and make a gift to It All Starts Here!... https://t.co/TzigLREnsB

[Thor Halfdanarson @OncoThor]

Somatostatin analogs for high G2 (Ki-67 10-20%) and G3 NETs, worth trying or not? According to this retrospective study, the PFS in patients w/ high G2 NETs was 19 months vs. 6 months in G3. Patients with a higher liver tumor burden defined as >10% of liver volume had a shorter PFS but the number of patients was low.

Take home message: SSAs are reasonable as initial therapy in high G2 and G3 NETs assuming follow up is close and patients are offered more effective therapy such as PRRT upon progression.

https://t.co/G2sMasvfiA

[Lavanya Yohanathan @LYohanathan]

Exciting times for hai pump chemotherapy for unresectable icca ! Great work by @BasGrootKoerkam

[Syed A. Ahmad @SyedAAhmad5]

PUMP 2 trial now published. Congrats ⁦@BasGrootKoerkam⁩

Hepatic Arterial Infusion Pump Chemotherapy in Patients With Unresectable Intrahepatic Cholangiocarcinoma—PUMP-2 ⁦@JCO_ASCO⁩ ⁦@GregWilson152⁩ ⁦@IHPBA⁩ https://t.co/uSvGM5ap6p

[Gladdy Lab @GladdyLab]

Brilliant Nina Axelrad talk by Prof Carol Swallow #CTOS2025 ⁦@ctosociety⁩
🌎collaboration ⁦@TARPSWG⁩ to better advance RPS pt outcomes - continued progress!
⁦@UofTSurgery⁩ ⁦@SinaiHealth⁩ ⁦@pmcancercentre⁩

[Thor Halfdanarson @OncoThor]

To operate or not on panc NETs <2 cm…? The answer is NOT.

Excellent presentation by @spartelli on the long term outcomes of the ASPEN trial. Almost 1000 patients observed w/o resection and progression was uncommon, mets rare and survival the same as with resection.

[Patricio Polanco @PatricioPolanc0]

Please join us for this Society of Surgical Oncology discussion about the Intersection of Hepatobiliary and Peritoneal Surface Malignancies with experts panelists: David Bartlett, @DavidCabaMD , @ColinCourtMD Deepa Magge, @SyedKazmiMD @KLafaro Jula Verapoong @SinzianaDumitra

[Lavanya Yohanathan @LYohanathan]

Excellent work and long awaited results of ASPEN trial by @spartelli !!! It is safe to observe pancreatic net <2cm!!

[Julie Hallet @HalletJulie]

📢 Small NF PanNETs can/should be observed

#ASPEN🏔️ @spartelli #ESMO25
👥Prospective multi-centre cohort 1️⃣0️⃣0️⃣0️⃣ PanNETs <2cm

An image 🏞️ is worth 1000 words👇🏻
For resection:
😳NNT 276
⚠️NNH 6
✅No difference in OS surgery vs active surveillance

👏Congrats on landmark work!

[Lavanya Yohanathan @LYohanathan]

@spartelli @myESMO Looking forward to hear about the results

[Lavanya Yohanathan @LYohanathan]

At the Mayo Clinic alumni reception @ #ACS2025 such a wonderful time to connect with colleagues and friends @MayoClinic @MayoSurgery @MayoClinicSurg @DrJudyBoughey and our favorite @FlavioRochaMD

[Lavanya Yohanathan @LYohanathan]

@DrJudyBoughey @MayoClinicSurg @ZAlHilliMD @chibaAkiko I am loving this mayo blue jumpsuit @DrJudyBoughey 🩷

[Lavanya Yohanathan @LYohanathan]

@DrJashDatta @SylvesterCancer @KReissMD @PennCancer @GretelTerrero @PeterHoseinMD Would love to know more about this ? What are you all doing for screening of these patients @DrJashDatta

[Julie Hallet @HalletJulie]

🌀Do CRLM truly disappear after chemo?

DREAM study:👥233 pts
MRI + CT most accurate
❌63% truly nonviable
👀24% visible on intraop US
No change OS with resection vs not (small numbers)

🤔If disappeared CRLM: plan resection or trust it disappeared?

https://t.co/jf9R5ko3Bj

[Lavanya Yohanathan @LYohanathan]

@HalletJulie @alegronchi @AM_Covelli_MD @SinzianaDumitra @_CSSO @SocSurgOnc @CAGS_ACCG Wow so many of my favorite people in one frame!!

[ECOG-ACRIN Cancer Research Group @eaonc]

In #ClinicalTrial EA2222/PUMP, investigators are testing #PumpChemo in addition to SOC chemo versus SOC chemo alone for patients with unresectable #ColorectalCancer liver metastases. For more: https://t.co/xBChV6GALe cc: @michael_lidsky

[Lavanya Yohanathan @LYohanathan]

@MichaelDAngeli2 This sounds amazing!

[Michael Lidsky, MD, FACS @michael_lidsky]

Shout it from the rooftops! Determination of technical resectability is best left to the liver surgeon, and all patients deserve to be evaluated by one. But the decision to operate, and when, remains a multidisciplinary decision.